Please assess the completion status of the following clinical trial:

Trial Title: Study of Intravitreal REGN2176-3 in Participants With Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Men or women ≥50 years of age~2. Active subfoveal CNV secondary to AMD as evidenced by FA in the study eye, as determined by the reading center, including juxtafoveal lesions that affect the fovea~3. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye at the screening visit~4. Provide signed informed consent~Key Exclusion Criteria:~1. Any prior treatment with anti-VEGF treatment in the study eye~2. Any prior treatment (ie, systemic or ocular treatment) with PDGF or PDGFR inhibitors~3. Dense fibrotic scar or atrophy in the study eye involving the center of the fovea~4. Presence of retinal pigment epithelial tears or rips involving the macula in the study eye~5. Prior vitrectomy in the study eye~6. Any history of macular hole of stage 2 and above in the study eye~7. Any intraocular or periocular surgery within 3 months of day 1 in the study eye, except lid surgery~8. History of corneal transplant in the study eye~9. Evidence of diabetic retinopathy or diabetic macular edema in either eye~10. Positive serum human chorionic gonadotropin/urine pregnancy test at the screening or baseline visit

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REGN2176-3 (1 mg: 2 mg) (Type: EXPERIMENTAL): Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
- REGN2176-3 (3 mg: 2 mg) (Type: EXPERIMENTAL): Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
- Intravitreal Aflibercept Injection (IAI) 2 mg (Type: EXPERIMENTAL): IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.
- REGN2176-3 (3 mg: 2 mg) to IAI 2 mg (Type: EXPERIMENTAL): Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.
- IAI 2 mg to REGN2176-3 (3 mg:2 mg) (Type: EXPERIMENTAL): IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.

Based on this trial design, predict the completion outcome and termination type (if applicable).